The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
New acetabular system enhances precision, stability and robotic compatibility in total hip arthroplasty
Rs. 40 cr buyback, 200% dividend announced
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Subscribe To Our Newsletter & Stay Updated
